NCT05981209View on ClinicalTrials.gov

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Dexamethasone

Given IV or PO

PROCEDURE

Echocardiography

Undergo ECHO

BIOLOGICAL

Elotuzumab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Mezigdomide

Given PO

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Abdullah Khan

OTHER